Condition
Endometrial Cancer, Endometrial Neoplasm
Total Trials
3
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
33.3%
1 terminated out of 3 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
0
Data Visualizations
Phase Distribution
2Total
P 1 (2)
Trial Status
Not Yet Recruiting2
Terminated1
Clinical Trials (3)
Showing 3 of 3 trials
NCT05180474Phase 1Terminated
GEN1047 for Solid Tumors - First in Human (FIH) Trial
NCT07006103Not Yet RecruitingPrimary
Precision Medicine Applied to the Study of Endometrial Cancer: Application of NGS for Molecular Classification
NCT06620029Phase 1Not Yet Recruiting
BMX-001 + Paclitaxel in Adult Patients With Advanced, Recurrent, Metastatic Ovarian or Endometrial Cancer
Showing all 3 trials